Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Table 1 Key baseline patient demographics and characteristics

Characteristic	Overall (N = 130)^a	Patients with best response of SD (n = 32)
Age, median (range), y	61 (20–83)	61.5 (24–79)
ECOG performance status^b
0	46 (35)	10 (31)
1	66 (51)	17 (53)
2	17 (13)	5 (16)
International Prognostic Index, n (%)
<2	31 (24)	7 (22)
≥2	99 (76)	25 (78)
PTCL subtype based on central review, n (%)
PTCL-NOS	69 (53)	16 (50)
AITL	27 (21)	8 (25)
ALK-1-negative ALCL	21 (16)	5 (16)
Other	13 (10)c	3 (9)^d
Stage III/IV at diagnosis, n (%)	91 (70)	20 (63)
Number of prior therapies, n (%)
1	38 (29)	13 (41)
2	44 (34)	11 (34)
3	19 (15)	3 (9)
4	15 (12)	4 (13)
>4	14 (11)	1 (3)
Type of prior therapy, n (%)
Chemotherapy	129 (99)	31 (97)
Monoclonal antibody therapy	20 (15)	3 (9)
Other immunotherapy	14 (11)	1 (3)
Radiation	31 (24)	8 (25)
ASCT	21 (16)	3 (9)
Refractory to most recent therapy, n (%)	49 (38)	8 (25)

ASCT autologous stem cell transplant
^a PTCL histologically confirmed by central pathology review
^b One patient in the overall population had missing ECOG performance status at baseline
^cIncludes enteropathy-associated TCL (6), subcutaneous panniculitis-type TCL (3), ALK-1-positive ALCL (1), cutaneous γδ TCL (1), extranodal NK/TCL nasal type (1), and transformed mycosis fungoides (1)
^dIncludes enteropathy-type TCL (1), subcutaneous panniculitis-like TCL (1), and cutaneous γδ TCL (1)

ISSN: 1756-8722